A Novel Anti-CXCR4 Antibody for Relapsed/Refractory Multiple Myeloma

Video

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.

Clinical Pearls

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.

  • This trial analyzed the anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide and low-dose dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.
  • Patients achieved a nearly 56% overall response rate.
  • Many patients on the trial were refractory to lenalidomide.

More on this study > >

Recent Videos
Related Content
Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Jordyn Sava
April 1st 2025
Article

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Read More

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Binod Dhakal, MD, MS;Jordyn Sava
June 14th 2024
Podcast

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

Jordyn Sava;Ben Derman, MD
February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More